Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice

Kim, Nayoun; Im, Keon-Il; Lim, Jung-Yeon; Jeon, Eun-Joo; Nam, Young-Sun; Kim, Eun-Jung; Cho, Seok-Goo
October 2013
Annals of Hematology;Oct2013, Vol. 92 Issue 10, p1295
Academic Journal
Mesenchymal stem cells (MSCs) have emerged as a therapeutic approach in a range of medical fields, including regenerative medicine, cancer, autoimmune diseases, and inflammatory diseases, because of their unique properties of tissue repair and major histocompatibility complex-unmatched immunosuppression. Because both in vitro and in vivo findings demonstrate that MSCs possess potent immunoregulatory functions, there has been increasing interest in the role of MSCs in allogeneic hematopoietic stem cell transplantation, especially in the prevention and treatment of graft-versus-host disease (GVHD). GVHD is a major cause of transplantation-related mortality, and conventional immunosuppressants frequently fail to treat patients suffering from GVHD. Following Ringden's pilot study that used third-party MSCs to treat a steroid-refractory GVHD patient, MSCs have created growing interest as a therapeutic agent for GVHD. There have been further studies which demonstrated the potentials of MSC treatment in steroid-refractory GVHD, de novo GVHD, and also GVHD prevention. However, MSCs still present limitations. The need for MSCs to be 'licensed' in a pro-inflammatory environment, especially in the presence of interferon gamma, allows only a narrow window for their administration. Thus, their effects have been less clear as a preventive measure before the inflammatory environment of GVHD is established and also when administered during a chronic setting where MSCs may be alternatively licensed. In this review, we focus on the immunomodulatory properties of MSCs and their effects in relation to GVHD. Given the efficacy of MSCs in murine models of GVHD and their safety in clinical trials, it is crucial that larger clinical trials are conducted and further modifications are investigated.


Related Articles

  • Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Haentzschel, I.; Freiberg-Richter, J.; Platzbecker, U.; Kiani, A.; Schetelig, J.; Illmer, T.; Ehninger, G.; Schleyer, E.; Bornhäuser, M. // Bone Marrow Transplantation;Jul2008, Vol. 42 Issue 2, p113 

    As low trough levels of mycophenolic acid (MPA) have been measured in recipients of allo-SCTs, we performed a pilot study targeting mycophenolate mofetil (MMF) doses according to the MPA area under the concentration (AUC) levels. Twenty-nine patients were transplanted from matched sibling (n=7)...

  • Mesenchymal Stromal Cells Do Not Increase the Risk of Viral Reactivation Nor the Severity of Viral Events in Recipients of Allogeneic Stem Cell Transplantation. Lucchini, Giovanna; Dander, Erica; Pavan, Fabio; Di Ceglie, Irene; Balduzzi, Adriana; Perseghin, Paolo; Gaipa, Giuseppe; Algarotti, Alessandra; Introna, Martino; Rambaldi, Alessandro; Rovelli, Attilio; Biondi, Andrea; Biagi, Ettore; D'Amico, Giovanna // Stem Cells International;2012, p1 

    Mesenchymal stromal cells (MSC) are tested in clinical trials to treat graft versus host disease (GvHD) after stem cell transplantation (SCT). In vitro studies demonstrated MSC's broad immunosuppressive activity. As infections represent a major risk after SCT, it is important to understand the...

  • Management of Chronic Graft-Versus-Host Disease. Baker, Melissa; McKiernan, Phyllis // Clinical Journal of Oncology Nursing;Aug2011, Vol. 15 Issue 4, p429 

    Chronic graft-versus-host disease (GVHD) is an immune-mediated disorder that adversely affects quality of life and clinical outcomes in patients following hematopoietic stem cell transplantation. Conventional treatment of GVHD includes prolonged and high-dose corticosteroids; however, those...

  • Physicians Poster AbstractsEBMT 2011.  // Bone Marrow Transplantation;Apr2011 Supplement, Vol. 46, pS90 

    The article presents abstracts on medical topics which include "Personalized modelling-based gene selection for developing an early acute GvHD diagnosis support system," by M. Cuzzola and colleagues, "TCR-like positive neutrophil reconstitution following haematopoietic stem cell...

  • The emerging role of mesenchymal stem cells in tissue engineering. Dehghanifard, Ali; Shahjahani, Mohammad; Soleimani, Masoud; Saki, Najmaldin // International Journal of Hematology-Oncology & Stem Cell Researc;Jan2013, Vol. 7 Issue 1, p43 

    The article discusses the role of mesenchymal stem cells (MSCs) in tissue engineering. It cites clinical studies demonstrate high capacity of MScs in improvement of allogeneic stem cell transplantation and in reducing graft-versus-host disease (GVHD) complications. It cites the approach of using...

  • Bone marrow mesenchymal stem cells reduce the antitumor activity of cytokine-induced killer/natural killer cells in K562 NOD/SCID mice. Yang Li; Yu-hua Qu; Yan-feng Wu; Xiao-ping Wang; Jing Wei; Wen-ge Huang; Dun-hua Zhou; Jianpei Fang; Ke Huang; Shao-liang Huang // Annals of Hematology;Aug2011, Vol. 90 Issue 8, p873 

    doptive cellular immunotherapy is an important treatment to eliminate residual tumor cells after hematopoietic stem-cell transplantation. Bone marrow mesenchymal stem cells (MSC) have previously been shown to exert immunoregulation functions, including inhibition of proliferation and killing...

  • Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation. Libura, J; Hoffmann, T; Passweg, J R; Gregor, M; Favre, G; Tichelli, A; Gratwohl, A // Bone Marrow Transplantation;10/15/99, Vol. 24 Issue 8, p925 

    There is growing evidence for a graft-versus-myeloma effect following allogeneic stem cell transplantation. We add to this evidence by reporting complete remission achieved by withdrawal of immunosuppression in a patient with multiple myeloma progressing after HLA-identical sibling peripheral...

  • A Nasogastric Feeding Trial for Patients Undergoing Allogeneic Stem Cell Transplantation. Hyman, Jodi; Horne, Annabel; Cheng, Jessica // Nursing Monograph;Jan2007, p20 

    Patients undergoing allogeneic peripheral blood stem cell transplantation (PBSCT) are often malnourished resulting in increased morbidity and mortality. PBSCT recipients are prone to varying degrees of nutritional insult resulting from side effects of chemotherapy and radiotherapy such as...

  • Graft-versus-host disease/ Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Massenkeil, G.; Rackwitz, S.; Genvresse, I.; Rosen, O.; Dorken, B.; Arnold, R. // Bone Marrow Transplantation;12/15/2002, Vol. 30 Issue 12, p899 

    Presents a study that evaluated the safety and efficacy of basiliximab in the therapy of steroid-refractory graft-versus-host disease after allogeneic stem cell transplantation. Methodology; Results; Discussion.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics